Harmony Biosciences (HRMY) Competitors $26.76 -5.31 (-16.56%) Closing price 09/24/2025 04:00 PM EasternExtended Trading$26.75 -0.01 (-0.03%) As of 09:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HRMY vs. GRFS, RYTM, LEGN, ABVX, RNA, CYTK, AXSM, CRSP, NUVL, and MRUSShould you be buying Harmony Biosciences stock or one of its competitors? The main competitors of Harmony Biosciences include Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Abivax (ABVX), Avidity Biosciences (RNA), Cytokinetics (CYTK), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Nuvalent (NUVL), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry. Harmony Biosciences vs. Its Competitors Grifols Rhythm Pharmaceuticals Legend Biotech Abivax Avidity Biosciences Cytokinetics Axsome Therapeutics CRISPR Therapeutics Nuvalent Merus Grifols (NASDAQ:GRFS) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations. Which has more volatility & risk, GRFS or HRMY? Grifols has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Is GRFS or HRMY more profitable? Harmony Biosciences has a net margin of 23.44% compared to Grifols' net margin of 0.00%. Harmony Biosciences' return on equity of 26.34% beat Grifols' return on equity.Company Net Margins Return on Equity Return on Assets GrifolsN/A N/A N/A Harmony Biosciences 23.44%26.34%17.71% Which has higher earnings and valuation, GRFS or HRMY? Grifols has higher revenue and earnings than Harmony Biosciences. Grifols is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$7.81B0.87$169.80M$1.178.43Harmony Biosciences$772.53M1.99$145.49M$3.108.63 Do insiders & institutionals have more ownership in GRFS or HRMY? 86.2% of Harmony Biosciences shares are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Comparatively, 23.6% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts rate GRFS or HRMY? Grifols presently has a consensus target price of $10.30, indicating a potential upside of 4.46%. Harmony Biosciences has a consensus target price of $50.20, indicating a potential upside of 87.59%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Harmony Biosciences is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.60Harmony Biosciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media favor GRFS or HRMY? In the previous week, Harmony Biosciences had 15 more articles in the media than Grifols. MarketBeat recorded 17 mentions for Harmony Biosciences and 2 mentions for Grifols. Grifols' average media sentiment score of 1.13 beat Harmony Biosciences' score of 0.97 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harmony Biosciences 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive SummaryHarmony Biosciences beats Grifols on 13 of the 16 factors compared between the two stocks. Get Harmony Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRMY vs. The Competition Export to ExcelMetricHarmony BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.85B$3.15B$5.77B$10.41BDividend YieldN/A2.36%5.68%4.62%P/E Ratio8.6320.7676.0426.42Price / Sales1.99392.57521.33168.33Price / Cash10.8845.9137.5661.52Price / Book2.319.8312.876.39Net Income$145.49M-$52.73M$3.29B$271.13M7 Day Performance-17.99%1.84%0.80%0.93%1 Month Performance-28.49%7.48%4.91%7.52%1 Year Performance-28.24%19.92%67.75%30.06% Harmony Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRMYHarmony Biosciences4.6367 of 5 stars$26.76-16.6%$48.70+82.0%-29.2%$1.85B$772.53M8.63200Trending NewsAnalyst ForecastGap DownHigh Trading VolumeGRFSGrifols3.9265 of 5 stars$9.70-0.4%$10.30+6.2%+13.3%$6.70B$7.81B8.2923,822News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.4644 of 5 stars$99.00+3.1%$101.57+2.6%+89.1%$6.38B$130.13M-32.89140Positive NewsAnalyst ForecastLEGNLegend Biotech3.182 of 5 stars$34.08+0.2%$74.22+117.8%-27.4%$6.28B$627.24M-38.732,609Positive NewsABVXAbivax2.5976 of 5 stars$82.21-0.1%$99.43+20.9%+629.9%$6.22BN/A0.0061Gap UpRNAAvidity Biosciences2.0992 of 5 stars$42.34+3.1%$68.32+61.4%-1.8%$5.99B$10.90M-11.89190Analyst ForecastCYTKCytokinetics4.2364 of 5 stars$48.25-0.8%$75.71+56.9%-8.3%$5.82B$18.47M-9.46250Trending NewsAnalyst ForecastAnalyst RevisionAXSMAxsome Therapeutics4.8637 of 5 stars$117.49+1.3%$177.86+51.4%+30.1%$5.79B$385.69M-23.17380Insider TradeCRSPCRISPR Therapeutics3.2216 of 5 stars$62.10-0.4%$71.50+15.1%+30.5%$5.67B$37.31M-11.44460Analyst ForecastNUVLNuvalent2.9892 of 5 stars$78.90+2.9%$119.50+51.5%-21.5%$5.53BN/A-16.1040MRUSMerus2.8939 of 5 stars$69.19+1.4%$90.54+30.9%+43.2%$5.16B$36.13M-12.5837 Related Companies and Tools Related Companies Grifols Alternatives Rhythm Pharmaceuticals Alternatives Legend Biotech Alternatives Abivax Alternatives Avidity Biosciences Alternatives Cytokinetics Alternatives Axsome Therapeutics Alternatives CRISPR Therapeutics Alternatives Nuvalent Alternatives Merus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HRMY) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
